Publication: Effects of polymorphisms in the MTHFR gene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients
0
0
Issued Date
2022
Resource Type
Language
eng
File Type
application/pdf
ISSN
2234943X
Rights Holder(s)
มหาวิทยาลัยศรีนครินทรวิโรฒ
Bibliographic Citation
Journal of Pure and Applied Microbiology. Vol 16, No.1 (2022), p.402-418
Suggested Citation
Atasilp C., Lenavat R., Vanwong N., Chansriwong P., Sirachainan E., Reungwetwattana T., Jinda P., Aiempradit S., Sirilerttrakul S., Chamnanphon M., Puangpetch A., Sankuntaw N., Satapornpong P., Sukasem C. Effects of polymorphisms in the MTHFR gene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients. Journal of Pure and Applied Microbiology. Vol 16, No.1 (2022), p.402-418. doi:10.3389/fonc.2022.916650 Retrieved from: https://hdl.handle.net/20.500.14740/9218
Abstract
Background: The two common methylenetetrahydrofolate reductase (MTHFR) polymorphisms 677G>A and 1298A>C may have been affecting 5-FU toxicity in cancer patients for decades. Drug efficacy has also been shown by previous studies to be affected. In this study, we investigated the effects of these polymorphisms on 5-FU hematological toxicity and treatment efficacy, to provide enhanced pharmacological treatment for cancer patients. Methods: This is a retrospective study involving 52 Thai colorectal cancer patients who were treated with 5-FU based therapy, using TaqMAN real-time PCR to genotype the MTHFR polymorphisms (677G>A and 1298A>C). The toxicity and response rate were assessed using standardized measures. Results: Neutropenia was significantly more likely to be experienced (P=0.049, OR=7.286, 95% CI=0.697-76.181) by patients with the MTHFR 677G>A polymorphism, in the same way as leukopenia (P =0.036, OR=3.333, 95%CI=2.183-5.090) and thrombocytopenia (P<0.001, OR=3.917, 95%CI=2.404-6.382). The MTHFR 1298A>C polymorphism had no statistical association with hematological toxicity in 5-FU treatment. The response rate to 5-FU was not significantly affected by these two polymorphisms. Conclusion: The MTHFR polymorphism 677G>A is a significant risk factor for developing leukopenia, neutropenia and thrombocytopenia as toxic effects of 5-FU therapy in cancer patients. Therefore, patients receiving 5-FU-based therapy should be aware of their polymorphisms as one risk factor for experiencing severe toxicity. Copyright © 2022 Atasilp, Lenavat, Vanwong, Chansriwong, Sirachainan, Reungwetwattana, Jinda, Aiempradit, Sirilerttrakul, Chamnanphon, Puangpetch, Sankuntaw, Satapornpong and Sukasem.